Contact information Verified work emails, personal emails, and direct dials — unlocked in one click.
Work email
•••••@adctherapeutics.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••
Free to start · No credit card required
Current company ADC Therapeutics
Biotechnology Research · 257 employees · Founded 2011 · Lausanne, Switzerland
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs).
Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. We are a pioneer in the ADC field with specialized capabilities unique to ADCs from clinical to manufacturing and commercialization with a proven track record that includes an approved and marketed product.
Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC.
Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer.
For more information, please visit https://www.adctherapeutics.com/.